Howard I. Scher, MD | Authors

Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate Cancer

August 15, 2014

This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 2

September 01, 2002

Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1

August 01, 2002

Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a

Combined-Modality Therapy for Bladder Cancer

September 01, 1997

Radical cystectomy remains standard management for patients with locally advanced T2 through T4, N0, M0 transitional cell carcinoma of the urinary bladder.